# US 2010/0168094 A1 · Modulators of cystic fibrosis transmembrane conductance regulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168094 A1
- Document ID: US20100168094A1
- Status: Published application
- Kind: A1
- Application number: 12/643,188
- Filed: 2009-12-21
- Published: 2010-07-01
- Earliest claimed: 2008-12-30
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: Hayley Binch; Dennis Hurley; Lev T.D. Fanning; Peter D.J. Grootenhuis; Martyn Botfield; Fredrick Van Goor
- Web page: https://patentgrep.com/patent/US20100168094A1

## CPC

- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/10: Laxatives
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 265/36: condensed with one six-membered ring
- C07D 279/16: condensed with one six-membered ring
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.

## Claims

### Claim 1

A compound of Formula I:
or pharmaceutically acceptable salts thereof, wherein:
Ar1 is a 5-6 membered aromatic monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally fused to a 5-12 membered monocyclic or bicyclic, aromatic ring, wherein each ring contains 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ar1 has m substituents, each independently selected from —WRW;
W is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by O, —CO—, —CS—, —COCO—, —CONR′—, —CONR′NR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —C(O)NR′—, —OCONR′—, —NR′NR′, —NR′NR′CO—, —NR′CO—, —S—, —SO, —SO2—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—;
RW is independently R′, halo, NO2, CN, CF3, OCF3, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
m is 0-5;
k is 0-3;
each R1 is independently —X—RX;
X is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR′—, —CONR′NR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —OCONR′—, —NR′NR′, —NR′NR′CO—, —NR′CO—, —S—, —SO, —SO2—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—;
RX is independently halo, NO2, CN, CF3, OCF3, OCH3, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen, halo, or a C1-C6 aliphatic group optionally substituted with —X—RX;
R3 is hydrogen or a C1-C6 aliphatic group optionally substituted with —X—RX;
R′ is independently selected from hydrogen, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R′ are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
provided that
when R2 is hydrogen and m is 0, Ar1 is not phenyl, pyridyl or pyrimidinyl;
when R2 is hydrogen, m is 1, and Ar1 is phenyl or pyridyl, —WRW is not halo, —C1-C3 aliphatic, —SMe, —OC1-C3 aliphatic, —CN, —NH2 or —CONH2;
when R2 is hydrogen, R3 is hydrogen, m is 2, Ar1 is phenyl, pyridyl or pyrimidinyl, and one instance of —WRW is halo, —CH3, —CH2CH3, or —OCH3, the second instance of —WRW is not —CH3, —CH2CH3, —OCH3, or halo; and
when R2 is hydrogen, R3 is hydrogen, m is 3 and Ar1 is phenyl, all instances of —WRW are not simultaneously halo or C1-C3 aliphatic.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein Ar1 is selected from:
wherein ring A1 5-6 membered aromatic monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
A1 and A2, together, is an 8-14 membered aromatic, bicyclic, or tricyclic aromatic ring, wherein each ring contains 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein A1 is an optionally substituted 6 membered aromatic ring having 0-4 heteroatoms, wherein said heteroatom is nitrogen.

### Claim 4 (depends on 2)

The compound according to claim 2, wherein A1 is phenyl.

### Claim 5 (depends on 2)

The compound according to claim 2, wherein A2 is an optionally substituted 6 membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 6 (depends on 2)

The compound according to claim 2, wherein A2 is an optionally substituted 5-membered aromatic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 7 (depends on 2)

The compound according to claim 2, wherein A2 is a 5-membered aromatic ring having 1-2 nitrogen atoms.

### Claim 8 (depends on 2)

The compound according to claim 2, wherein A2 is selected from:
wherein ring A2 is fused to ring A1 through two adjacent ring atoms.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R1 is halo, CN, CH3, CF3, OCF3, OCH3 or SO2Me.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein R2 is hydrogen.

### Claim 11 (depends on 1)

The compound according to claim 1, wherein R2 is methyl.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein R3 is hydrogen.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein R2 and R3 are hydrogen.

### Claim 14 (depends on 2)

The compound according to claim 2, wherein said compound has Formula IIA or Formula IIB:

### Claim 15 (depends on 2)

The compound according to claim 2, wherein said compound has Formula IIIA,
wherein:
each of X1, X2, X3, X4, and X5 is independently selected from CH or N.

### Claim 16 (depends on 15)

The compound according to claim 15, wherein X1, X2, X3, X4, and X5 taken together in compound of Formula IIIA is a ring selected from pyridyl, pyrazinyl, or pyrimidinyl.

### Claim 17 (depends on 15)

The compound according to claim 15, wherein said compound has Formula IIIA-1:
wherein each of WRW2 and WRW4 is independently selected from CN, CF3, OCF3, —OC1-C3 aliphatic, —C≡CCH2N(R′)(R′), halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, 3-12 membered bicyclic, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said bicyclic, heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) optionally substituted phenyl or phenoxy, or optionally substituted C3-C7 heterocyclic, wherein said heterocyclic has up to 3 heteroatoms selected from O, S, or N.

### Claim 18 (depends on 15)

The compound according to claim 15, wherein said compound has the Formula IIIA-2:
wherein each of WRW2 and WRW4 is independently selected from CN, CF3, OCF3, —OC1-C3 aliphatic, —C≡CCH2N(R′)(R′), halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, 3-12 membered bicyclic, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said bicyclic, heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) optionally substituted phenyl or phenoxy, or optionally substituted C3-C7 heterocyclic, wherein said heterocyclic has up to 3 heteroatoms selected from O, S, or N.

### Claim 19 (depends on 15)

The compound according to claim 15, wherein said compound has the Formula IIIA-3:
wherein each of WRW2 and WRW4 is independently selected from CN, CF3, OCF3, —OC1-C3 aliphatic, —C≡CCH2N(R′)(R′), halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, 3-12 membered bicyclic, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said bicyclic, heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) optionally substituted phenyl or phenoxy, or optionally substituted C3-C7 heterocyclic, wherein said heterocyclic has up to 3 heteroatoms selected from O, S, or N.

### Claim 20 (depends on 2)

The compound according to claim 2, wherein said compound has Formula IIIB, Formula IIIC, Formula IIID, or Formula IIIE:
wherein:
each of X1, X2, X3, X4, and X5 is independently selected from CH or N; and
X6 is O, S, NH or NR′.

### Claim 21 (depends on 20)

The compound according to claim 20 wherein X1, X2, X3, or X5, taken together with ring A2 in compounds of Formula IIIB, or Formula IIIC is an optionally substituted ring selected from

### Claim 22 (depends on 2)

The compound according to claim 2, wherein said compound has Formula IVA.

### Claim 23 (depends on 2)

The compound according to claim 2, wherein said compound has Formula IVB, or Formula IVC:

### Claim 24 (depends on 23)

The compound according to claim 23, wherein ring A2 of Formula IVB or IVC is an optionally substituted, saturated, unsaturated, or aromatic 5-7 membered ring with 0-3 heteroatoms selected from O, S, or N.

### Claim 25 (depends on 22)

The compound according to claim 22, wherein said compound has Formula VA-1A:
wherein each of WRW2 and WRW4 is independently selected from CN, CF3, OCF3, —SO2R′, —OC1-C3 aliphatic, —C≡CCH2N(R′)(R′), halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)3N(R′)(R′), —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′), optionally substituted phenyl or phenoxy, or optionally substituted C3-C7 heterocyclic, wherein said heterocyclic has up to 3 heteroatoms selected from O, S, or N and
WRW5 is selected from halo, —OH, OR′, —OCF3, NH2, CN, CHF2, NHR′, N(R′)2, —NHC(O)R′, —NHC(O)OR′, NHSO2R′, —OR′, CH2OH, CH2N(R′)2, C(O)OR′, C(O)N(R′)2, SO2NHR′, SO2N(R′)2, OSO2N(R′)2, OSO2CF3, optionally substituted C1-C6 straight or branched aliphatic, optionally substituted 3-12 membered cycloaliphatic, or CH2NHC(O)OR′.

### Claim 26 (depends on 25)

The compound according to claim 25 wherein WRW4 is a C1-C6 straight or branched aliphatic, or a 3-12 membered cycloaliphatic, WRW4 is —OH or OR′ and WRW2 is —C≡CCH2N(R′)(R′), —(CH2)3N(R′)(R′), —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) or —N(R′)(R′).

### Claim 27 (depends on 22)

The compound according to claim 22, wherein said compound has the Formula VA-1B:
wherein each of WRW2 and WRW4 is independently selected from CN, CF3, OCF3, —OC1-C3 aliphatic, —C≡CCH2N(R′)(R′), halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, 3-12 membered bicyclic, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said bicyclic, heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW2 and WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) optionally substituted phenyl or phenoxy, or optionally substituted C3-C7 heterocyclic, wherein said heterocyclic has up to 3 heteroatoms selected from O, S, or N.

### Claim 28 (depends on 27)

The compound according to claim 27 wherein WRW4 is a substituted C1-C6 straight or branched aliphatic, C3-C7 heterocyclic, 3-12 membered cycloaliphatic, or 3-12 membered bicyclic and WRW2 is —C≡CCH2N(R′)(R′), —(CH2)3N(R′)(R′), —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) or —N(R′)(R′).

### Claim 29 (depends on 22)

The compound according to claim 22, wherein said compound has the Formula VA-1C:
wherein WRW3 is selected from halo, —OH, —OCF3, NH2, CN, CHF2, NHR′, N(R′)2, —NHC(O)R′, —NHC(O)OR′, NHSO2R′, —OR′, CH2OH, CH2N(R′)2, C(O)OR′, C(O)N(R′)2, SO2NHR′, SO2N(R′)2, OSO2N(R′)2, OSO2CF3, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, or CH2NHC(O)OR′ and
WRW4 is independently selected from CN, CF3, OCF3, —SO2R′, —OC1-C3 aliphatic, halo, C1-C6 straight or branched aliphatic, 3-12 membered cycloaliphatic, phenyl, C5-C10 heteroaryl or C3-C7 heterocyclic, wherein said heteroaryl or heterocyclic has up to 3 heteroatoms selected from O, S, or N, wherein said WRW4 is independently and optionally substituted with up to three substituents selected from —OR′, —CF3, —OCF3, SR′, S(O)R′, SO2R′, —SCF3, halo, C1-C6 straight or branched aliphatic, CN, —COOR′, —COR′, —O(CH2)2N(R′)(R′), —O(CH2)N(R′)(R′), —CON(R′)(R′), —(CH2)2OR′, —(CH2)OR′, CH2CN, optionally substituted phenyl or phenoxy, —N(R′)(R′), —NR′C(O)OR′, —NR′C(O)R′, —(CH2)2N(R′)(R′), or —(CH2)N(R′)(R′).

### Claim 30 (depends on 29)

The compound according to claim 29 wherein WRW4 is a substituted C1-C6 straight or branched aliphatic, C3-C7 heterocyclic, 3-12 membered cycloaliphatic, or 3-12 membered bicyclic and WRW2 is —C≡CCH2N(R′)(R′), —(CH2)3N(R′)(R′), —(CH2)2N(R′)(R′), —(CH2)N(R′)(R′) or —N(R′)(R′).

### Claim 31 (depends on 22)

The compound according to claim 22, wherein said compound has the Formula VA-1D:
ring A is a 5-7 membered monocyclic or bicyclic, heterocyclic or heteroaryl ring optionally substituted with up to n occurrences of -Q-RQ,
Q is W;
RQ is RW; and
m is 0-4; and
n is 0-4.

### Claim 32 (depends on 22)

The compound according to claim 22, wherein said compound has the Formula VA-2:
wherein:
ring B is a 5-7 membered monocyclic or bicyclic, heterocyclic or heteroaryl ring optionally substituted with up to n occurrences of -Q-RQ,
Q is W;
RQ is RW; and
m is 0-4; and
n is 0-4.

### Claim 33 (depends on 23)

The compound according to claim 23, wherein said compound has the Formula VB-2:
wherein:
ring A2 is a phenyl or a 5-6 membered heteroaryl ring, wherein ring A2 and the phenyl ring fused thereto together have up 4 substituents independently selected from WRW; and
m is 0-4.

### Claim 34 (depends on 33)

The compound according to claim 33 wherein ring A2 is an optionally substituted 5-membered ring selected from pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, or triazolyl.

### Claim 35 (depends on 33)

The compound according to claim 33, wherein ring A2 is selected from:
wherein said ring is optionally substituted.

### Claim 36 (depends on 33)

The compound according to claim 33 wherein said compound has the Formula VB-3:
wherein:
G4 is hydrogen, halo, CN, CF3, CHF2, CH2F, optionally substituted C1-C6 aliphatic, aryl-C1-C6 alkyl, or a phenyl, wherein G4 is optionally substituted with up to 4 WRW substituents; wherein up to two methylene units of said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with —CO—, —CONR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —OCONR′—, —NR′CO—, —S—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—;
G5 is hydrogen, CN, or an optionally substituted C1-C6 aliphatic;
wherein said indole ring system is further optionally substituted with up to 3 substituents independently selected from WRW.

### Claim 37 (depends on 36)

The compound according to claim 36, wherein G4 is hydrogen, and G5 is C1-C6 aliphatic, wherein said aliphatic is optionally substituted with C1-C6 alkyl, halo, cyano, or CF3, and wherein up to two methylene units of said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with —CO—, —CONR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —OCONR′—, —NR′CO—, —S—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—.

### Claim 38 (depends on 36)

The compound according to claim 36, wherein G4 is hydrogen, and G5 is cyano, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, cyanomethyl, methoxyethyl, CH2C(O)OMe, (CH2)2—NHC(O)O-tert-But, or cyclopentyl.

### Claim 39 (depends on 36)

The compound according to claim 36, wherein G5 is hydrogen, CN or CF3, and G4 is halo, C1-C6 aliphatic or phenyl, wherein said aliphatic or phenyl is optionally substituted with C1-C6 alkyl, halo, cyano, or CF3, wherein up to two methylene units of said C1-C6 aliphatic or C1-C6 alkyl is optionally replaced with —CO—, —CONR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —OCONR′—, —NR′CO—, —S—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—.

### Claim 40 (depends on 35)

The compound according to claim 35, wherein G5 is hydrogen, CN or CF3, and G4 is halo, ethoxycarbonyl, t-butyl, 2-methoxyphenyl, 2-ethoxyphenyl, (4-C(O)NH(CH2)2—NMe2)-phenyl, 2-methoxy-4-chloro-phenyl, pyridine-3-yl, 4-isopropylphenyl, 2,6-dimethoxyphenyl, sec-butylaminocarbonyl, ethyl, t-butyl, or piperidin-1-ylcarbonyl.

### Claim at position 41

41-43. (canceled)

### Claim 44 (depends on 1)

The compound according to claim 1, which is selected from the group consisting of:

### Claim 45 (depends on 1)

A pharmaceutical composition comprising a compound of Formula I according to claim 1 and a pharmaceutically acceptable carrier or adjuvant.

### Claim 46 (depends on 45)

The pharmaceutical composition according to claim 45, further comprising an additional agent selected from a mucolytic agent, a bronchodialator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of Formula I, or a nutritional agent.

### Claim 47 (depends on 46)

The pharmaceutical composition according to claim 46, wherein said additional agent is a CFTR modulator other than a compound of Formula I.

### Claim 48

A method of modulating CFTR activity comprising the step of contacting said CFTR with a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 is a 5-6 membered aromatic monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally fused to a 5-12 membered monocyclic or bicyclic, aromatic ring, wherein each ring contains 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ar1 has m substituents, each independently selected from —WRW;
W is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of W are optionally and independently replaced by O, —CO—, —CS—, —COCO—, —CONR′—, —CONR′NR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —C(O)NR′—, —OCONR′—, —NR′NR′, —NR′NR′CO—, —NR′CO—, —S—, —SO, —SO2—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—;
RW is independently R′, halo, NO2, CN, CF3, OCF3, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
m is 0-5;
k is 0-3;
each R1 is independently —X—RX;
X is a bond or is an optionally substituted C1-C6 alkylidene chain wherein up to two methylene units of X are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR′—, —CONR′NR′—, —CO2—, —OCO—, —NR′CO2—, —O—, —NR′CONR′—, —OCONR′—, —NR′NR′, —NR′NR′CO—, —NR′CO—, —S—, —SO, —SO2—, —NR′—, —SO2NR′—, NR′SO2—, or —NR′SO2NR′—;
RX is independently halo, NO2, CN, CF3, OCF3, OCH3, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R2 is hydrogen, halo, or a C1-C6 aliphatic group optionally substituted with —X—RX;
R3 is hydrogen or a C1-C6 aliphatic group optionally substituted with —X—RX;
R′ is independently selected from hydrogen, an optionally substituted group selected from a C1-C8 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 7-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R′ are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 49 (depends on 1)

A method of treating or lessening the severity of a disease in a patient, wherein said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, pancreatic insufficiency, osteoporosis, osteopenia, Gorham's Syndrome, chloride channelopathies, myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, Primary Ciliary Dyskinesia (PCD), PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia, or Sjogren's disease, said method comprising the step of administering to said patient an effective amount of a compound according to claim 1.

### Claim 50 (depends on 49)

The method according to claim 49, wherein said disease is cystic fibrosis.

### Claim 51 (depends on 1)

A method of treating or lessening the severity of a disease in a patient, wherein said disease is associated with reduced CFTR function due to mutations in the gene encoding CFTR or environmental factors, said method comprising the step of administering to said patient an effective amount of a compound according to claims 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein disease is cystic fibrosis, chronic bronchitis, recurrent bronchitis, acute bronchitis, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), female infertility caused by congenital absence of the uterus and vagina (CAUV), idiopathic chronic pancreatitis (ICP), idiopathic recurrent pancreatitis, idiopathic acute pancreatitis, chronic rhinosinusitis, primary sclerosing cholangitis, allergic bronchopulmonary aspergillosis, diabetes, dry eye, constipation, allergic bronchopulmonary aspergillosis (ABPA), bone diseases, and asthma.

### Claim 53 (depends on 1)

A method of treating or lessening the severity of a disease in a patient, wherein said disease is associated with normal CFTR function, said method comprising the step of administering to said patient an effective amount of a compound according to claim 1.

### Claim 54 (depends on 53)

The method of claim 53, wherein disease is chronic obstructive pulmonary disease (COPD), chronic bronchitis, recurrent bronchitis, acute bronchitis, rhinosinusitis, constipation, chronic pancreatitis, recurrent pancreatitis, and acute pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, liver disease, hereditary emphysema, gallstones, gasgtro-esophageal reflux disease, gastrointestinal malignancies, inflammatory bowel disease, constipation, diabetes, arthritis, osteoporosis, and osteopenia.

### Claim 55 (depends on 53)

The method of claim 53, wherein the disease is hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II, polyendocrinopathy/hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal pallidoluysian, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, Gorham's Syndrome, chloride channelopathies, myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's disease, hyperekplexia, epilepsy, hyperekplexia, lysosomal storage disease, Angelman syndrome, Primary Ciliary Dyskinesia (PCD), PCD with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia, or Sjogren's disease.

### Claim 56 (depends on 1)

A method of modulating CFTR activity in a biological sample comprising the step of contacting said CFTR with a compound according to claim 1.

### Claim 57 (depends on 1)

A kit for use in measuring the activity of CFTR or a fragment thereof in a biological sample in vitro or in vivo, comprising:
(i) a composition comprising a compound of Formula I according to claim 1;
(ii) instructions for:
a) contacting the composition with the biological sample;
b) measuring activity of said CFTR or a fragment thereof.

### Claim 58 (depends on 57)

The kit of claim 57, further comprising instructions for:
a) contacting an additional compound with the biological sample;
b) measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and
c) comparing the activity of said CFTR or a fragment thereof in the presence of said additional compound with the activity of said CFTR or a fragment thereof in the presence of a composition of Formula I.

### Claim at position 57

59-87. (canceled)

### Claim 88 (depends on 58)

The kit according to claim 58, wherein the step of comparing the activity of said CFTR or a fragment thereof provides a measure of the density of said CFTR or a fragment thereof.
